- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03094832
Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002) (MOSAIC)
A Phase 1/2 Study of ARQ 092 (Miransertib) in Subjects With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Expanded Access
Contacts and Locations
Study Locations
-
-
New South Wales
-
Waratah NSW, New South Wales, Australia, 2298
- Hunter Genetics ( Site 0201)
-
-
-
-
-
Catania, Italy, 95123
- Universita di Catania ( Site 0088)
-
Roma, Italy, 00168
- Fondazione Policlinico Universitario A. Gemelli ( Site 0052)
-
-
Roma
-
Rome, Roma, Italy, 00165
- Ospedale Pediatrico Bambino Gesu ( Site 0087)
-
-
-
-
Barcelona
-
Esplugues de Llobregat, Barcelona, Spain, 08950
- Hospital Sant Joan ( Site 0601)
-
-
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Children's Hospital of Atlanta ( Site 0107)
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Ann & Robert H. Lurie Children's Hospital of Chicago ( Site 0101)
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Boston Children's Hospital ( Site 0089)
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center ( Site 0102)
-
-
Texas
-
Houston, Texas, United States, 77030
- Texas Children's Hospital ( Site 0104)
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Childrens Hospital ( Site 0103)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Part A
- Signed informed consent and, when applicable, signed assent
- Male or female participants ≥ 2 years old with body surface area (BSA) of ≥ 0.33 m^2
- Have a clinical diagnosis of PROS or PS with documented somatic PIK3CA or serine-threonine protein kinase (AKT1) mutations
- Archival or fresh overgrowth tissue sample available to be shipped to Sponsor or designee
- Have poor prognosis, significant morbidity, and/or progressive disease (e.g., worsening of the disease/increase in number or size of the overgrowth lesions in the last 12 months)
- Have measurable disease (at least one overgrowth lesion that can be accurately measured in size by imaging and/or linear or circumference measure)
- Adequate organ function based on screening laboratory values
- If a female is of child-bearing potential, documentation of a negative pregnancy test is required prior to enrollment. Sexually active participants (male and female) must agree to use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse while on study and for up to 90 days after ending treatment
- Ability to complete the Quality of Life (QoL) questionnaires by the participant or his/her caregiver
Part B:
- Signed consent form and when applicable, signed assent
- Archival or fresh overgrowth tissue sample available to be shipped to Sponsor or designee
- Except for Cohort 4, clinically progressive or worsening disease defined as an increase in number or size of the overgrowth lesion(s) in the last 6 months as assessed by the Investigator
- Adequate organ function based on screening laboratory values
- Male or female participants of child-producing potential must agree to use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse during the study and for 90 days after the last dose of miransertib
- Ability to complete the study questionnaires by the participant or his/her caregiver
Cohort 1 (PROS) specific criteria
- Male or female participants ≥ 2 years and ≤30 years of age with BSA of ≥ 0.33 m2
- Have clinical diagnosis of PROS per Diagnostic Criteria for PROS and documented somatic PIK3CA variant
Have at least one lesion that can be measured by study- standardized volumetric MRI (eligibility to be confirmed by blinded independent central imaging review
- Cohort 2 (PS) specific criteria
- Male or female participants ≥ 2 years and ≤18 years of age with BSA of ≥ 0.33 m2
- Have clinical diagnosis of PS per Diagnostic Criteria for PS and documented somatic AKT1 variant
Have at least one plantar cerebriform connective tissue nevus (CCTN) and pre-CCTN lesion that can be measured by standardized photography
- Cohort 3 specific criteria: Male or female participants ≥2 years old with BSA of ≥ 0.33 m2 and who fail to meet the eligibility criteria for Cohorts 1 or 2
- Cohort 4 (PROS or PS) specific criteria: participants previously treated with miransertib or currently receiving miransertib under Compassionate Use/Expanded Access. Participants should meet the age criterion by/on the date of the first dose, Cycle 1 Day 1
Exclusion Criteria
Part A:
- History of Type 1 or 2 uncontrolled diabetes mellitus requiring regular medication (other than metformin or other oral hypoglycemic agents) or fasting glucose ≥ 160 mg/dL (if > 12 years old) and ≥ 180 mg/dL (if ≤ 12 years old) at the screening visit
History of significant cardiac disorders:
- Myocardial infarction (MI) or congestive heart failure defined as Class II-IV per the New York Heart Association (NYHA) classification within 6 months of the first dose of miransertib (MI occurring > 6 months of the first dose of miransertib will be permitted)
- Grade 2 (per NCI CTCAE version 4.03) or worse conduction defect (e.g., right or left bundle branch block); left ventricular ejection fraction (LVEF) < 50% assessed by echocardiogram/multigated acquisition (MUGA) scan
- Major surgery, radiotherapy, or immunotherapy within four weeks of the first dose of miransertib
- Any experimental systemic therapy for the purpose of treating PROS or PS (e.g., sirolimus, everolimus, high dose steroids) within two weeks of the first dose of miransertib, except for participants who were previously or are currently treated with miransertib under a Compassionate Use/Expanded Access program
- Intolerance of or severe toxicity attributed to v-Akt murine thymoma viral oncogene homolog (AKT) inhibitors (e.g., miransertib, uprosertib, afuresertib, ipatasertib)
- Concurrent severe uncontrolled illness not related to PROS or PS (ongoing or active infection, known human immunodeficiency virus (HIV) infection, malabsorption syndrome, psychiatric illness/substance abuse/social situation that would limit compliance with study requirements)
- Pregnant or breastfeeding
- Inability to comply with study evaluations or to follow drug administration guidelines
Part B
- History of Type 1 diabetes mellitus or Type 2 uncontrolled diabetes mellitus requiring regular medication (other than metformin or other oral hypoglycemic agents) or fasting glucose ≥ 160 mg/dL (if > 12 years old) and ≥ 180 mg/dL (if ≤ 12 years old) at the screening visit
History of significant cardiac disorders:
- Myocardial infarction (MI) or congestive heart failure defined as Class II-IV per the New York Heart Association (NYHA) classification within 6 months of the first dose of miransertib (MI occurring > 6 months of the first dose of miransertib will be permitted)
- Grade 2 (per current version of National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE]) or worse conduction defect (e.g., right or left bundle branch block)
- Major surgery or locoregional therapy within four weeks of the first dose of miransertib
- Any experimental systemic therapy for the purposes of treating PROS or PS (e.g., sirolimus, everolimus, high dose steroids) within two weeks of the first dose of miransertib
- Intolerance of or severe toxicity attributed to AKT inhibitors (e.g., miransertib, uprosertib, afuresertib, ipatasertib)
- Concurrent severe uncontrolled illness not related to PROS or PS (e.g. ongoing or active infection, known HIV infection, malabsorption syndrome, psychiatric illness/substance abuse/social situation that would limit compliance with study requirements)
- Pregnant or breastfeeding
- Inability to comply with study evaluations or to follow drug administration guidelines
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A: Miransertib PROS/PS
During Cycles 1-3, participants with either PROS (phosphatidylinositol- 4,5-bisphosphate 3-kinase, catalytic subunit alpha [PIK3CA]-related Overgrowth Spectrum) or PS (Proteus syndrome) received miransertib 15 mg/m^2 once daily (QD) (each cycle length = 28 days).
From Cycles 4-48 or until disease progression, unacceptable toxicity, or discontinuation, participants received miransertib dose titrated to 25 mg/m^2 and then titrated to 35 mg/m^2 orally QD at the investigator's discretion.
|
Miransertib capsules administered orally at an initial dose of 15 mg/m^2 or 25 mg/m^2 QD and then titrated up to 25 mg/m^2 or 35 mg/m^2 QD at the investigator's discretion.
Other Names:
|
Experimental: Part B: Miransertib PROS (Cohort 1)
During Cycles 1-3, participants with PROS who have a measurable lesion by volumetric magnetic resonance imaging (MRI) received miransertib 15 mg/m^2 QD (each cycle length = 28 days).
From cycles 4-48 or until disease progression, unacceptable toxicity, or discontinuation, participants received miransertib dose titrated to 25 mg/m^2 orally QD at the investigator's discretion.
|
Miransertib capsules administered orally at an initial dose of 15 mg/m^2 or 25 mg/m^2 QD and then titrated up to 25 mg/m^2 or 35 mg/m^2 QD at the investigator's discretion.
Other Names:
|
Experimental: Part B: Miransertib PS (Cohort 2)
During Cycles 1-3, participants with PS who have a measurable lesion by standardized digital photography received miransertib 15 mg/m^2 QD (each cycle length = 28 days).
From cycles 4-48 or until disease progression, unacceptable toxicity, or discontinuation, participants received miransertib dose titrated to 25 mg/m^2 orally QD at the investigator's discretion.
|
Miransertib capsules administered orally at an initial dose of 15 mg/m^2 or 25 mg/m^2 QD and then titrated up to 25 mg/m^2 or 35 mg/m^2 QD at the investigator's discretion.
Other Names:
|
Experimental: Part B: Miransertib PROS/PS (Cohort 3)
During Cycles 1-3, participants with PROS or PS who do not meet all the eligibility criteria for Cohorts 1 or 2 received miransertib 15 mg/m^2 QD (each cycle length = 28 days).
From cycles 4-48 or until disease progression, unacceptable toxicity, or discontinuation, participants received miransertib dose titrated to 25 mg/m^2 orally QD at the investigator's discretion.
|
Miransertib capsules administered orally at an initial dose of 15 mg/m^2 or 25 mg/m^2 QD and then titrated up to 25 mg/m^2 or 35 mg/m^2 QD at the investigator's discretion.
Other Names:
|
Experimental: Part B: Miransertib Compassionate Use/Expanded Access (Cohort 4)
During cycles 1-48 (each cycle length = 28 days) or until disease progression, unacceptable toxicity, or discontinuation, participants previously treated with miransertib or currently receiving miransertib under Compassionate Use/Expanded Access continued to receive the current dose of miransertib (did not exceed 25 mg/m^2).
|
Miransertib capsules administered orally at an initial dose of 15 mg/m^2 or 25 mg/m^2 QD and then titrated up to 25 mg/m^2 or 35 mg/m^2 QD at the investigator's discretion.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Experienced an Adverse Event (AE)
Time Frame: Up to approximately 48 months
|
An AE was defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product and does not imply any judgment about causality.
|
Up to approximately 48 months
|
Number of Participants Who Discontinued Study Treatment Due to an AE
Time Frame: Up to approximately 45 months
|
An AE was defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product and does not imply any judgment about causality.
|
Up to approximately 45 months
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Neoplasms
- Disease
- Congenital Abnormalities
- Musculoskeletal Diseases
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Bone Diseases
- Musculoskeletal Abnormalities
- Abnormalities, Multiple
- Enterobacteriaceae Infections
- Bone Diseases, Developmental
- Limb Deformities, Congenital
- Hamartoma Syndrome, Multiple
- Hamartoma
- Neoplasms, Multiple Primary
- Syndrome
- Proteus Infections
- Proteus Syndrome
Other Study ID Numbers
- 7075-002
- Mosaic (ArQule)
- ARQ 092-103 (Other Identifier: ArQule)
- MK-7075-002 (Other Identifier: Merck)
- 2016-000558-37 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome
-
Novartis PharmaceuticalsAvailablePIK3CA-Related Overgrowth Spectrum (PROS)
-
Novartis PharmaceuticalsRecruitingPIK3CA-related Overgrowth Spectrum (PROS)United States, Canada, Spain, Switzerland, France, United Kingdom, Germany, Italy, China, Hong Kong, Netherlands, Norway
-
Novartis PharmaceuticalsActive, not recruitingPIK3CA-related Overgrowth Spectrum (PROS)Spain, France, Ireland, United States
-
Novartis PharmaceuticalsCompletedPIK3CA-Related Overgrowth Spectrum (PROS)Spain, France, Australia, United States, Ireland
-
Merck Sharp & Dohme LLCActive, not recruitingPIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)United States, Australia, Brazil, Italy, United Kingdom
-
National Human Genome Research Institute (NHGRI)CompletedGenetics | Growth Disorder | PIK3CA-Related Overgrowth Spectrum (PROS)United States
-
ArQule, Inc. (a wholly owned subsidiary of Merck...No longer availableGrowth Disorders | Proteus Syndrome | PIK3CA-Related Overgrowth Spectrum (PROS)
-
National Human Genome Research Institute (NHGRI)Children's National Research Institute; Uniformed Services University of the...RecruitingProteus Syndrome | PIK3CA Related Overgrowth SpectrumUnited States
-
Novartis PharmaceuticalsRecruitingPIK3CA-related Overgrowth SpectrumUnited States
-
Centre Hospitalier Universitaire DijonTerminated
Clinical Trials on Miransertib
-
National Human Genome Research Institute (NHGRI)CompletedProteus SyndromeUnited States
-
National Human Genome Research Institute (NHGRI)Recruiting
-
Merck Sharp & Dohme LLCActive, not recruitingPIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)United States, Australia, Brazil, Italy, United Kingdom